ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
0 hedge funds and large institutions have $0 invested in ELITE PHARMACEUTICAL in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $2.38K → $0 (-$2.38K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$2.38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Fisher Asset Management
Camas,
Washington
| – | -$2.38K | -82,000 | Closed |
|
ELI Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2023, worth a combined $0 — down 100% from $2.38K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ELI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Fisher Asset Management, exiting entirely with an estimated $2.38K sold.
- 0 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2023, down from 1 in Q1 2023.
- Funds reported $0 of ELITE PHARMACEUTICAL stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest ELITE PHARMACEUTICAL seller in Q2 2023 was Fisher Asset Management, an estimated $2.38K sold.
Based on aggregated 13F filings for Q2 2023.